Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Guthrie

Showing results (1-10 of 38) with videos related to

Pageof 4
Sort By:
Clinical Cornerstone|May 5, 2009
Recent advances in cardiovascular risk reduction: implications of ONTARGETRobert Guthrie
Current Atherosclerosis Reports|December 17, 2008
Should we treat all primary prevention patients with statins?Robert Guthrie
Clinical Medicine Insights. Cardiology|November 17, 2010
Niacin or ezetimibe for patients with, or at risk of coronary heart diseaseRobert Guthrie
The Physician and Sportsmedicine|August 25, 2018
Physical activity following acute concussion and persistent postconcussive symptoms in children and adolescentsRobert Guthrie
Journal of Law and Medicine|June 19, 2007
The Australian legal framework for stress claimsRobert Guthrie
Postgraduate Medicine|March 14, 2020
Linagliptin in patients with type 2 diabetes and cardiovascular and/or renal disease: results from a cardiovascular and renal outcomes trialRobert Guthrie
Journal of Law and Medicine|November 12, 2015
Criminal injuries compensation: Protecting vulnerable applicantsRobert Guthrie
Postgraduate Medicine|December 6, 2016
Canagliflozin use in Type I diabetes mellitusRobert Guthrie
Journal of Law and Medicine|June 18, 2010
Sick leave and workers' compensation for police officers in AustraliaRobert Guthrie
Postgraduate Medicine|January 4, 2018
Canagliflozin and cardiovascular and renal events in type 2 diabetesRobert Guthrie
Pageof 4

Showing results (1-10 of 38) with videos related to

Sort By:
Pageof 4
Clinical Cornerstone|May 5, 2009
Recent advances in cardiovascular risk reduction: implications of ONTARGETRobert Guthrie
Current Atherosclerosis Reports|December 17, 2008
Should we treat all primary prevention patients with statins?Robert Guthrie
Clinical Medicine Insights. Cardiology|November 17, 2010
Niacin or ezetimibe for patients with, or at risk of coronary heart diseaseRobert Guthrie
The Physician and Sportsmedicine|August 25, 2018
Physical activity following acute concussion and persistent postconcussive symptoms in children and adolescentsRobert Guthrie
Journal of Law and Medicine|June 19, 2007
The Australian legal framework for stress claimsRobert Guthrie
Postgraduate Medicine|March 14, 2020
Linagliptin in patients with type 2 diabetes and cardiovascular and/or renal disease: results from a cardiovascular and renal outcomes trialRobert Guthrie
Journal of Law and Medicine|November 12, 2015
Criminal injuries compensation: Protecting vulnerable applicantsRobert Guthrie
Postgraduate Medicine|December 6, 2016
Canagliflozin use in Type I diabetes mellitusRobert Guthrie
Journal of Law and Medicine|June 18, 2010
Sick leave and workers' compensation for police officers in AustraliaRobert Guthrie
Postgraduate Medicine|January 4, 2018
Canagliflozin and cardiovascular and renal events in type 2 diabetesRobert Guthrie
Pageof 4